129 related articles for article (PubMed ID: 33484811)
1. Adjuvanted vaccines driven protection against visceral infection in BALB/c mice by Leishmania donovani.
Goyal DK; Keshav P; Kaur S
Microb Pathog; 2021 Feb; 151():104733. PubMed ID: 33484811
[TBL] [Abstract][Full Text] [Related]
2. Immune induction by adjuvanted Leishmania donovani vaccines against the visceral leishmaniasis in BALB/c mice.
Goyal DK; Keshav P; Kaur S
Immunobiology; 2021 Mar; 226(2):152057. PubMed ID: 33545508
[TBL] [Abstract][Full Text] [Related]
3. Studies on the protective efficacy of freeze thawed promastigote antigen of Leishmania donovani along with various adjuvants against visceral leishmaniasis infection in mice.
Thakur A; Kaur H; Kaur S
Immunobiology; 2015 Sep; 220(9):1031-8. PubMed ID: 26001730
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis.
Thakur A; Kaur H; Kaur S
Parasitol Int; 2015 Feb; 64(1):70-8. PubMed ID: 25316605
[TBL] [Abstract][Full Text] [Related]
5. Potential of TLR agonist as an adjuvant in Leishmania vaccine against visceral leishmaniasis in BALB/c mice.
Goyal DK; Keshav P; Kaur S
Microb Pathog; 2021 Sep; 158():105021. PubMed ID: 34089789
[TBL] [Abstract][Full Text] [Related]
6. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
Nagill R; Kaur S
Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
[TBL] [Abstract][Full Text] [Related]
7. Immunization with antigenic extracts of Leishmania associated with Montanide ISA 763 adjuvant induces partial protection in BALB/c mice against Leishmania (Leishmania) amazonensis infection.
Cargnelutti DE; Salomón MC; Celedon V; García Bustos MF; Morea G; Cuello-Carrión FD; Scodeller EA
J Microbiol Immunol Infect; 2016 Feb; 49(1):24-32. PubMed ID: 24662018
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the immunogenicity and protective efficacy of killed Leishmania donovani antigen along with different adjuvants against experimental visceral leishmaniasis.
Thakur A; Kaur H; Kaur S
Med Microbiol Immunol; 2015 Aug; 204(4):539-50. PubMed ID: 25432859
[TBL] [Abstract][Full Text] [Related]
9. Leishmania donovani serine protease encapsulated in liposome elicits protective immunity in experimental visceral leishmaniasis.
Das P; Paik D; Naskar K; Chakraborti T
Microbes Infect; 2018 Jan; 20(1):37-47. PubMed ID: 28970116
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant effects of TLR agonist gardiquimod admixed with Leishmania vaccine in mice model of visceral leishmaniasis.
Goyal DK; Keshav P; Kaur S
Infect Genet Evol; 2021 Sep; 93():104947. PubMed ID: 34052416
[TBL] [Abstract][Full Text] [Related]
11. Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis.
Nagill R; Mahajan R; Sharma M; Kaur S
Parasitol Int; 2009 Dec; 58(4):359-66. PubMed ID: 19638322
[TBL] [Abstract][Full Text] [Related]
12. Studies on cocktails of 31-kDa, 36-kDa and 51-kDa antigens of Leishmania donovani along with saponin against murine visceral leishmaniasis.
Kaur H; Thakur A; Kaur S
Parasite Immunol; 2015 Apr; 37(4):192-203. PubMed ID: 25615543
[TBL] [Abstract][Full Text] [Related]
13. Leishmania major p27 gene knockout as a novel live attenuated vaccine candidate: Protective immunity and efficacy evaluation against cutaneous and visceral leishmaniasis in BALB/c mice.
Elikaee S; Mohebali M; Rezaei S; Eslami H; Khamesipour A; Keshavarz H; Eshraghian MR
Vaccine; 2019 May; 37(24):3221-3228. PubMed ID: 31047672
[TBL] [Abstract][Full Text] [Related]
14. Studies on the protective efficacy and immunogenicity of Hsp70 and Hsp83 based vaccine formulations in Leishmania donovani infected BALB/c mice.
Kaur J; Kaur T; Kaur S
Acta Trop; 2011 Jul; 119(1):50-6. PubMed ID: 21530477
[TBL] [Abstract][Full Text] [Related]
15. Live Attenuated Leishmania donovani Centrin Knock Out Parasites Generate Non-inferior Protective Immune Response in Aged Mice against Visceral Leishmaniasis.
Bhattacharya P; Dey R; Dagur PK; Joshi AB; Ismail N; Gannavaram S; Debrabant A; Akue AD; KuKuruga MA; Selvapandiyan A; McCoy JP; Nakhasi HL
PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004963. PubMed ID: 27580076
[TBL] [Abstract][Full Text] [Related]
16. A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis.
Oliveira-da-Silva JA; Machado AS; Ramos FF; Tavares GSV; Lage DP; Mendonça DVC; Pereira IAG; Santos TTO; Martins VT; Carvalho LM; Freitas CS; Ludolf F; Reis TAR; Bandeira RS; Silva AM; Costa LE; Oliveira JS; Duarte MC; Roatt BM; Teixeira AL; Coelho EAF
Cell Immunol; 2020 Oct; 356():104194. PubMed ID: 32827943
[TBL] [Abstract][Full Text] [Related]
17. 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity.
Choudhury R; Das P; De T; Chakraborti T
Immunobiology; 2013 Jan; 218(1):114-26. PubMed ID: 22440312
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
Ravindran R; Maji M; Ali N
Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194
[TBL] [Abstract][Full Text] [Related]
19. Adjuvantation of whole-killed Leishmania vaccine with anti-CD200 and anti-CD300a antibodies potentiates its efficacy and provides protection against wild-type parasites.
Singh R; Anand A; Mahapatra B; Saini S; Singh A; Singh S; Kumar V; Das P; Singh S; Singh RK
Mol Immunol; 2023 Nov; 163():136-146. PubMed ID: 37778149
[TBL] [Abstract][Full Text] [Related]
20. Studies on the protective efficacy of second-generation vaccine along with standard antileishmanial drug in Leishmania donovani infected BALB/c mice.
Joshi J; Kaur S
Parasitology; 2014 Apr; 141(4):554-62. PubMed ID: 24618257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]